Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Ahmed Sawas, MD, Helen Ma, MD, Andrei Shustov, MD, Pamela Hsu, MS, Gajanan Bhat, Mark Acosta, PharmD, Steven M. Horwitz, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 4050.

https://doi.org/10.1182/blood-2019-127155

Published: 2019

Journal Articles

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Mark Acosta, PharmD, Arrash Darban, PharmD, MS, Matthew Gitlin, PharmD

Blood (2019) 134 (Supplement_1): 5869.

https://doi.org/10.1182/blood-2019-124990

Published: 2019

Journal Articles

Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study

Frederick Lansigan, MD, Steven M Horwitz, MD, Lauren C Pinter-Brown, MD, Kenneth R Carson, MD, Andrei R Shustov, MD, Steven T. Rosen, MD, Barbara Pro, MD, Eric D. Hsi, MD, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A Bellm, MIM, Mark Acosta, PharmD, Francine M. Foss, MD

Blood (2016) 128 (22): 4150.

https://doi.org/10.1182/blood.V128.22.4150.4150

Published: 2016

Journal Articles

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

Francine Foss, MD, Nelida Sjak-Shie, MD, PhD, Andre Goy, MD, Eric Jacobsen, MD, Ranjana Advani, MD, Mitchell Smith, MD, PhD, Rami Komrokji, MD, Kelly Pendergrass, MD, Vanessa Bolejack, MPH, Karen Watts, Mark Acosta, PharmD

Blood (2007) 110 (11): 3449.

https://doi.org/10.1182/blood.V110.11.3449.3449

Published: 2007

Journal Articles

Phase II Study of Denileukin Diftitox (ONTAK®) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL) and Poor Bone Marrow Reserve.

Myron S. Czuczman, MD, Lauren Pinter-Brown, Mary Jo Lechowicz, Nancy Bartlett, MD, Hillard Lazarus, John Lister, Andre Goy, MD, Stephen Kahanic, MD, Peter Rosen, MD, Mark Acosta, PharmD

Blood (2006) 108 (11): 4724.

https://doi.org/10.1182/blood.V108.11.4724.4724

Published: 2006

Journal Articles

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

Francine Foss, MD, Madeleine Duvic, MD, Larisa Geskin, MD, Joseph Anderson, MD, Pierluigi Porcu, MD, Raymond J. Hohl, MD,PhD, Maureen Cooper, MD, Jasmine M. Zain, MD, John Zic, MD, Patrica Hibberd, MD,PhD, Mark Acosta, PharmD

Blood (2006) 108 (11): 2712.

https://doi.org/10.1182/blood.V108.11.2712.2712

Published: 2006

Journal Articles

A Phase II Study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in Patients with Newly-Diagnosed Aggressive T-Cell Lymphomas, the CONCEPT Trial: Interim Analysis.

Francine M. Foss, MD, Nelida Sjak-Shie, MD, PhD, Andre Goy, MD, Ranjana Advani, MD, Eric Jacobsen, MD, Mark Acosta, PharmD

Blood (2006) 108 (11): 2461.

https://doi.org/10.1182/blood.V108.11.2461.2461

Published: 2006

NARROW

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

Phase II Study of Denileukin Diftitox (ONTAK®) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL) and Poor Bone Marrow Reserve.

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

A Phase II Study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in Patients with Newly-Diagnosed Aggressive T-Cell Lymphomas, the CONCEPT Trial: Interim Analysis.

Email alerts

ASH Publications

American Society of Hematology

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

Phase II Study of Denileukin Diftitox (ONTAK®) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL) and Poor Bone Marrow Reserve.

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

A Phase II Study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in Patients with Newly-Diagnosed Aggressive T-Cell Lymphomas, the CONCEPT Trial: Interim Analysis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only